FEDERICO
PULIDO ORTEGA
Profesor asociado de Ciencias de la Salud
Hospital Universitario de Basurto
Bilbao, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Basurto (22)
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
2020
-
Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: A randomized trial
Annals of Internal Medicine, Vol. 172, Núm. 5, pp. 297-305
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
2018
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
2013
-
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine
Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 6, pp. 1373-1381
2010
-
Factores asociados con la no realización de la prueba de la tuberculina en una cohorte de pacientes VIH positivos
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 28, Núm. 4, pp. 215-221
2009
-
(Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))
Enfermedades Infecciosas y Microbiologia Clinica
-
Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
BMC Infectious Diseases, Vol. 10
-
HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations
Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258
2008
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
2007
-
Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain
International Journal of Tuberculosis and Lung Disease, Vol. 11, Núm. 11, pp. 1196-1202
2005
-
Once-daily antiretroviral therapy: Spanish Consensus Statement
Journal of Antimicrobial Chemotherapy, Vol. 56, Núm. 5, pp. 808-818